Literature DB >> 6316248

Inhibitors of the angiotensin I converting enzyme as antihypertensive drugs.

P A Van Zwieten, A De Jonge, P B Timmermans.   

Abstract

Inhibitors of the angiotensin I converting enzyme (captopril, enalapril) offer a new principle in the drug treatment of hypertension and congestive heart failure. The present survey deals with the mode of action of the converting enzyme inhibitors, including possible interference with the renin-angiotensin systems in the kidney, the vascular wall and the brain, with the kallikrein--bradykinin system and with the sympathetic nervous system, at both pre- and postjunctional sites. Furthermore, the haemodynamic pattern as well as the therapeutic applications are discussed, including the most important side-effects, contra-indications, interactions and clinical pharmacokinetic properties.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6316248     DOI: 10.1007/bf02332943

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  42 in total

Review 1.  Local regulation of adrenergic neurotransmission.

Authors:  T C Westfall
Journal:  Physiol Rev       Date:  1977-10       Impact factor: 37.312

2.  The effects of the antagonists of the renin-angiotensin system on cardiovascular response to lower-body subatmospheric pressure in the anaesthetized cat.

Authors:  S A Adigun; D P Clough; J Conway; R Hatton
Journal:  Clin Sci (Lond)       Date:  1980-06       Impact factor: 6.124

3.  Prolonged converting enzyme inhibition following captopril in patients with renal insuffficiency.

Authors:  B C Campbell; A N Shepherd; H L Elliott; K McLean; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-05       Impact factor: 4.335

Review 4.  Medical intelligence drug therapy: captopril.

Authors:  D G Vidt; E L Bravo; F M Fouad
Journal:  N Engl J Med       Date:  1982-01-28       Impact factor: 91.245

5.  Acute haemodynamic and hormonal effects of captopril are diminished by indomethacin.

Authors:  H Witzgall; F Hirsch; B Scherer; P C Weber
Journal:  Clin Sci (Lond)       Date:  1982-06       Impact factor: 6.124

6.  Captopril interferes with neurogenic vasoconstriction in the pithed rat by angiotensin-dependent mechanisms.

Authors:  R Hatton; D P Clough
Journal:  J Cardiovasc Pharmacol       Date:  1982 Jan-Feb       Impact factor: 3.105

7.  Acute effects of captopril on cardiopulmonary hemodynamics and renin-angiotensin-aldosterone and bradykinin profile in hypertension.

Authors:  S Mookherjee; G H Anderson; R Eich; N Hill; H Smulyan; D H Streeten; S Vardan; R Warner
Journal:  Am Heart J       Date:  1983-01       Impact factor: 4.749

8.  Captopril in primary pulmonary hypertension.

Authors:  C V Leier; D Bambach; S Nelson; J B Hermiller; P Huss; R D Magorien; D V Unverferth
Journal:  Circulation       Date:  1983-01       Impact factor: 29.690

9.  A specific orally active inhibitor of angiotensin-converting enzyme in man.

Authors:  R K Ferguson; G A Turini; H R Brunner; H Gavras; D N McKinstry
Journal:  Lancet       Date:  1977-04-09       Impact factor: 79.321

10.  Captopril kinetics.

Authors:  K L Duchin; S M Singhvi; D A Willard; B H Migdalof; D N McKinstry
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.